Site Search     
  A CHR Trial Investigation Outcomes of Exercise Training
  A Pull-Push Strategy for Lymphoma Immunotherapy
  Altered CD8+ T Cell Compartment in SLE Patients
  Biology and Diagnosis of HNPCC
  Center for Lupus Research
  CHAVI Innate Discovery
  Colon Cancer Prevention Program Project
  Consortium to Analyze Tolerogenic Dendritic Cells in Respiratory Syncytial Virus Infection
  Development of Neonatal Oxygen Therapy Information System to Support Oximetry Targets in Newborn Intensive Care Units
  Effect of S-adenosylmethionine on Blood Homocysteine
  Functional MR in Ischemic Cardiomyopathy
  Human Dendritic Cells and In Vivo Immunity to Biothreat
  Improving the Efficacy of Dendritic Cell Vaccines
  JC Virus and Tumor Formation in the Human Colon
  New Predictors of SLE Disease Activity
  NIAID Cooperative Center Luminex Facility
  Rural Hospital Collaborative for Excellence Using IT
Subpopulations of Human Dendritic Cells
  Targeting Langerhans Cells for Therapeutic Vaccination in Breast Cancer
  Transcriptional Signatures for Diagnosis of Different Spectra of Mycobacterium tuberculosis Infection and Characterization of the Immune Response during Latency or Active Disease
  Use of Microarrays to Understand Systemic Arthritis
Subpopulations of Human Dendritic Cells
Grant Number: 2R01CA078846-06
PI: Jacques F. Banchereau
Funding Organization: National Cancer Institute
Project Start: April 1, 1999
Project End: March 31, 2009

Abstract:

The immune system is composed of multiple effectors, T, B, NK and NKT cells each of which has been classified into subsets according to their functions. Immune effectors are dependent on Dendritic Cells (DCs) for their activation and their differentiation. And, as the immune effectors, DCs are also composed of distinct subsets. When considering human DCs, two main pathways are currently recognized: 1) The myeloid DCs separated into Langerhans Cells, specific to epidermis, and Interstitial DCs, present in other tissues and probably representing a collection of as yet unidentified subsets; 2) The plasmacytoid DCs, unique for their ability to produce large amounts of IFN alpha/beta in response to viral encounter. Recent findings of Interferon (IFN) biology reactivated immunologists' interest in this family of molecules. This includes i) the ability of IFN alpha/beta to activate immature DCs and the ability of IFN to induce the differentiation of monocytes into DCs (IFN-DCs), the theme of this proposal; ii) the activity of IFN alpha/beta in the generation of memory CD8+T cells and the stimulation of antibody responses; iii) the central role of IFN alpha/beta in the pathogenesis of Systemic Lupus Erythematosus. It is our hypothesis that the stimulatory effect of IFNalpha/beta on monocytes/myeloid DCs explain most, if not all the immunoregulatory role of IFN alpha/beta. This represents the essence of our proposal for two main reasons: 1) IFN-DCs circulate in patients suffering from SLE, 2) IFN-DCs may explain the therapeutic effects of IFN alpha in patients suffering from i) cancer such as melanoma, myeloma and AML or ii) infectious diseases such as hepatitis B. Four AIMS have been designed to provide an extensive characterization of IFN-DCs: AIM 1 analyzes the DCs themselves including their phenotype and their migration pattern. AIM 2 studies the functional effects of IFN-DCs on CD4+T cells. AIM 3 characterizes the differentiation of CD8+ T cells in response to IFN-DCs, with or without T cell help. AIM 4 identifies which IFN-DCs molecules skew the differentiation of T cells. This research, which focuses on the biology of human DC subsets has two important medical applications:1) better understanding of autoimmune diseases such as SLE; 2) the generation of more potent DC-based cancer vaccines.